Antiverse, a Cardiff, Wales, UK-based techbio company designing antibodies for challenging targets, raised £3.5M in Seed funding.
The round, which brought the total amount to £7.2M, was led by i&i Biotech Fund I (i&i Bio) and Kadmos Capital, with additional participation from existing investors InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub.
The company intends to use the funds to facilitate its growth, including appointments to strengthen the team and continued development of its antibody design programs, many in partnership with pharmaceutical companies.
Led by CEO Murat Tunaboylu, Antiverse uses a machine-learning-centred approach to design antibodies for challenging targets, helping to bring needed therapies to patients. The current version of the platform uses ‘target-specific libraries’. These libraries are designed by using structural and sequence data to generate a library with high confidence against the target. This enhances the predictive accuracy compared to traditional antibody libraries, enabling Antiverse to design antibodies for many challenging targets, including GPCRs and ion channels. The platform accelerates the antibody discovery process to 6 months.
The company has opened new facilities in Boston, MA, and Prague, Czech Republic, demonstrating its expansion.
FinSMEs
15/10/2024